Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ardelyx (ARDX)
Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue guidance -- a range it had reiterated just over three months earlier. Levi & Korsinsky is investigating potential securities law violations
NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Ardelyx (NASDAQ: ARDX) shares dropped 17.86% on August 7, 2026, closing at $4.00, after the Company cut its full-year 2026 IBSRELA revenue guidance to $350-$370 million from $410-$430 million. If you suffered a loss on your Ardelyx investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The $410-$430 million IBSRELA range had been reiterated on the Company's Q1 2026 earnings call on April 30, 2026. On August 6, 2026, after the close, Ardelyx reduced the range by approximately $60 million at the midpoint, citing increased payer utilization-management processes -- additional step edits and more stringent prior authorizations -- that slowed new-patient starts. Management stated on the call that the extent of the payer restrictions "was not something that one would anticipate."
In the same release, Ardelyx withdrew its long-term $750 million revenue target for XPHOZAH. Q2 2026 product revenue was $118.1 million with EPS of approximately $(0.07). The investigation concerns whether Ardelyx may not have adequately disclosed the payer dynamics affecting IBSRELA.
Shareholders who lost money on ARDX are encouraged to have their losses reviewed at no cost. You may also reach Joseph E. Levi, Esq. at (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
Frequently Asked Questions About the ARDX Investigation
Q: Who is conducting the ARDX investigation? A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased ARDX securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.
Q: How much did ARDX stock drop? A: Shares fell approximately 17.86% on August 7, 2026, closing at $4.00, after the Company reduced its full-year 2026 IBSRELA revenue guidance to $350-$370 million from $410-$430 million and withdrew its long-term $750 million XPHOZAH target. Investors who purchased shares and suffered losses may be eligible to seek compensation.
Q: Who is eligible to participate in the ARDX investigation? A: Investors who purchased ARDX stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do ARDX investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my ARDX shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ARDX and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
